



Dear {{accTitle}} {{accFname}} {{accLname}},
{{customRichText}}

Join Professor Manish Patel, Professor Bertrand Tombal and Professor Henry Woo in Sydney for a practical workshop focusing on a guide to prescribing Androgen Receptor Pathway Inhibitors (ARPIs) for Urologists. You are invited to attend in person or online.

WORKSHOP DETAILS



**A Urologist's Guide to
Prescribing ARPIs: Practical
Workshop**



**Tuesday 10th September
7:30 PM (AEST)
InterContinental Sydney,
117 Macquarie St, Sydney**

[Register Here](#)


Register on the link above to attend in person or online.

Agenda

7.30 pm	Introduction and Welcome	Prof. Manish Patel
7.35 pm	Data Overview: Unlocking the Potential of ARPIs in mHSPC	Prof. Bertrand Tombal

8.05 pm	Practical Guide: How to Prescribe ARPIs in the Australian Environment	Prof. Manish Patel
8.35 pm	Case Studies and Discussion	Prof. Patel, Prof. Tombal and Prof. Woo
9.25 pm	Meeting close	Prof. Manish Patel

Presenters



Manish I. Patel (Chair)

Professor of Urological Oncology, WCS, FMH, University of Sydney and Urological Cancer Surgeon, Westmead Hospital.



Bertrand Tombal, MD, PhD

Professor and Chairman
Department of Surgery
Cliniques universitaires Saint Luc
Université catholique de Louvain
Brussels, Belgium




Henry Woo

Director of Uro-Oncology and Professor of Robotic Cancer Surgery, Chris O'Brien Lifehouse. Head of Department of Urology, Blacktown Mount Druitt Hospitals. Professor, Australian National University.

I hope you can join us at the event. If you have any questions at all, please reach out to me using the contact details below.

Warm regards,

	<p>{{userName}} {{User.Title}}</p>
	<p>Astellas Pharma Australia Pty Ltd Suite 2.01, 2 Banfield Road, Macquarie Park, NSW 2113 Mobile: {{User.MobilePhone}} Email: {{userEmailAddress}}</p>

ARPI = Androgen Receptor Pathway Inhibitor.

XTANDI PBS information: Authority required for various advanced prostate cancer indications. Refer to www.pbs.gov.au and search 'XTANDI' for full authority information.

Please review full Xtandi Product Information before prescribing at <https://rss.medsinfo.com.au/ax/pi.cfm?product=axptand>

This meeting has been organised in accordance with the current edition of the Medicines Australia Code of Conduct ("Code") for the prescription medicines industry in Australia, Astellas Pharma Australia ("Astellas") ensures that any

company organised educational event complies with the applicable sections of the Code. Astellas will report any applicable transfers of value under the current Code reporting schedule. Astellas is committed to protecting your personal information and will only use it in accordance with the applicable data privacy laws and our Astellas Privacy Notice. For further information on how we process and protect your personal information and how you may exercise your data protection rights, please refer to our Privacy Notice at astellas.com/au/privacy-policy. If you have any questions or concerns, please contact us at privacyofficer-au@astellas.com.

This email contains information about Astellas' products, services or events. For more information on how we use and protect your information, please read our [Privacy Policy](#). You have received this email because you have previously given consent to receive information regarding Astellas products, services or events. You can withdraw your consent by emailing our privacy officer at privacyofficer-au@astellas.com.

If you no longer wish to receive electronic communications from Astellas, [unsubscribe here](#).



© 2024 Astellas Pharma Inc.

XTANDI™ is a registered trademark of Astellas Pharma, Inc. Astellas Pharma Australia Pty Ltd. ABN 81 147 915 482. Suite 2.01, 2 Banfield Road, Macquarie Park, NSW 2113.

MAT-AU-XTD-2024-00069
Date of Preparation: August 2024.